Michelle Brown, MD PhD, obtained her dual degree and post-doctoral training from the University of Utah and Huntsman Cancer Institute with focus on understanding the mechanisms of oncogenesis in pediatric oncology. As a Portfolio Lead at Moderna, Michelle is responsible for driving overarching development strategy/priorities across the individualized neoantigen therapy (INT) portfolio and ensuring harmonized design and execution of Moderna’s current and emerging mRNA-based oncology cancer therapeutics programs. Michelle empowers the INT Program Leaders and cross-functional teams to work towards delivering on the promise of mRNA science to create a new generation of transformative medicines for oncology patients. Prior to joining Modera, Michelle was a clinical development lead at Bristol-Myers Squibb, and was responsible for multiple novel immuno-oncology programs spanning from first in human to registration and helped launch the anti-PD1 and anti-CTLA4 checkpoint inhibitors into clinical practice. Early in her career, she worked in medical affairs specializing in immuno-oncology, biomarkers, and solid tumors. Her work has resulted in numerous peer-reviewed publications and supports the advancement of oncology treatment paradigms.